Pasithea to Exhibit at NF Conference After FDA Fast Track and Rare Pediatric Designations
KTTA•Pasithea will exhibit at the Children’s Tumor Foundation NF Conference from June 26–30 in Denver following FDA Fast Track and Rare Pediatric Disease designations for PAS-004. The Phase 1/1b macrocyclic MEK inhibitor trial enrolls NF1 patients with symptomatic, inoperable or recurrent plexiform neurofibromas.
1. Exhibition at CTF 2026 NF Conference
Pasithea will exhibit at the Children’s Tumor Foundation NF Conference in Denver from June 26–30, 2026, allowing direct engagement with physicians, researchers and patient advocates to discuss PAS-004 development.
2. Recent FDA Designations
PAS-004 received FDA Fast Track and Rare Pediatric Disease Designations for its next-generation macrocyclic MEK inhibitor program targeting NF1-associated tumors, potentially enabling expedited review and access to priority review vouchers.
3. Clinical Trial Pipeline
The company is conducting a Phase 1 trial in advanced cancer patients (NCT06299839) and a Phase 1/1b trial (NCT06961565) enrolling NF1 patients with symptomatic, inoperable or recurrent plexiform neurofibromas to evaluate safety and preliminary efficacy.
